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arly Experience With Percutaneous
ranscatheter Implantation of Heart Valve
rosthesis for the Treatment of End-Stage
noperable Patients With Calcific Aortic Stenosis
lain Cribier, MD, FACC,* He´le`ne Eltchaninoff, MD,* Christophe Tron, MD,* Fabrice Bauer, MD,*
arla Agatiello, MD,* Laurent Sebagh, MD,* Assaf Bash, PHD,§ Danielle Nusimovici, MD,§
. Y. Litzler, MD,† Jean-Paul Bessou, MD,† Martin B. Leon, MD, FACC‡
ouen, France; New York, New York; and Fort Lee, New Jersey
OBJECTIVES This study wad done to assess the results of percutaneous heart valve (PHV) implantation in
non-surgical patients with end-stage calcific aortic stenosis.
BACKGROUND Replacement of PHV has been shown to be feasible in animals and humans. We developed
a PHV composed of three pericardial leaflets inserted within a balloon-expandable stainless
steel stent. We report the acute and early follow-up results of the initial six PHV
implantations.
METHODS An anterograde approach was used in all cases. The PHV, crimped over a 22-mm diameter
balloon, was advanced through a 24-F sheath from the femoral vein to the aortic valve and
delivered by balloon inflation. Clinical, hemodynamic, and echocardiographic outcomes were
assessed serially.
RESULTS All patients were in New York Heart Association functional class IV. The PHV was
successfully delivered in five patients. Early migration with subsequent death occurred in one
patient who presented with a torn native valve. Acute hemodynamic and angiographic results
showed no residual gradient, mild (three patients) or severe (two patients) aortic regurgita-
tion, and patent coronary arteries. On echocardiography, the aortic valve area was increased
from 0.5 0.1 cm2 to 1.70 0.03 cm2 and the aortic regurgitation was paravalvular. Marked
and sustained hemodynamic and clinical improvement was observed after successful PHV
implants. The first three patients died of a non-cardiac cause at 18, 4, and 2 weeks,
respectively, and the other patients are alive at 8 weeks with no signs of heart failure.
CONCLUSIONS Implantation of the PHV can be achieved in patients with end-stage calcific aortic stenosis
and might become an important therapeutic option for patients not amenable to surgical valve
replacement. (J Am Coll Cardiol 2004;43:698–703) © 2004 by the American College of
Cardiology Foundation(
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srolonged life expectancy has resulted in an aging popula-
ion and, consequently, in an increased number of patients
ith degenerative calcific aortic stenosis. Surgical aortic
alve replacement is the treatment of choice for a vast
ajority of patients, offering symptomatic relief and im-
roving long-term survival (1,2). However, in a subset of
atients, mainly elderly patients with declining overall
ealth status or life-threatening comorbidities, aortic valve
eplacement is considered either too high risk or is contra-
ndicated. Balloon aortic valvuloplasty has been shown to
rovide temporary improvement of valvular function and
elief of symptoms in this non-surgical population (3,4), but
ts use is impaired by an unacceptably high mid-term
From the Departments of *Cardiology and †Cardiac Surgery, Charles Nicolle
ospital, University of Rouen, Rouen, France; ‡Cardiovascular Research Foundation,
enox Hill Hospital, New York, New York; and §Percutaneous Valve Technologies,
ort Lee, New Jersey. Drs. Cribier and Leon have stock ownership in Percutaneous
alve Technologies Inc., the company that designed and provided the percutaneous
alve used.
Manuscript received October 10, 2003; revised manuscript received November 24,c003, accepted November 24, 2003.within months) frequency of restenosis (5). Given the
imited therapeutic options in this subset of patients, there
as been interest in the development of a percutaneously
elivered bioprosthetic aortic heart valve.
Recent advances in stent and valve technologies have
emonstrated that percutaneous valve replacement is feasi-
le in both animals and humans. The integration of a
ioprosthetic valve and a stent was first demonstrated by
ndersen et al. in 1992 (6) in which a porcine bioprosthesis
ttached to a wire-based stent was delivered at various aortic
ites with satisfactory acute hemodynamic results. Since
hen, several other investigators have reported the implan-
ation by catheter delivery techniques of prosthetic valves of
arious designs in animal models (7–11). The first clinical
ases of percutaneous valve replacement in congenital heart
isease were reported by Bonhoeffer et al. (12,13), who
uccessfully implanted prosthetic heart valves made from
ovine jugular vein and mounted onto a platinum-iridium
tent and placed in stenotic right ventricle to pulmonary
onduits with good immediate and long-term results.
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February 18, 2004:698–703 Percutaneous Heart Valve in Aortic StenosisWe developed an original percutaneous heart valve
PHV) that was initially composed of three bovine pericar-
ial leaflets mounted within a stainless steel balloon-
xpandable stent (Percutaneous Valve Technologies Inc.,
ort Lee, New Jersey) with the goal of treating non-surgical
atients with end-stage aortic stenosis. The stent is 14 mm
n length and achieves a maximal diameter of 23 mm after
ull balloon inflation. Extensive ex-vivo testing and animal
mplantation studies have been completed (11), and we
eported the successful implantation of this PHV in a
atient with end-stage aortic stenosis (14). Since the first
ase, additional improvements to the PHV device have been
ade, and confirmatory pre-clinical testing (bench and
nimal) has been conducted with the goal of supporting
urther clinical studies. The new PHV is composed of three
quine pericardial leaflets mounted within a reinforced stent
rame (Fig. 1). Valve durability testing has completed 200
illion cycles (5 years). Our early clinical experiences in
atients with PHV implantation are reported.
ETHODS
atients. From April 2002 to August 2003, PHV implan-
ation was attempted in six patients, five males and one
emale, age 75  12 years (range 57 to 91 years) with severe
alcific aortic stenosis and multiple comorbidities (Table 1).
ach patient had been declined for surgery by cardiac
urgeons owing to hemodynamic instability and/or severe
omorbidities. Three of these patients were in cardiogenic
hock and all were in New York Heart Association
NYHA) functional class IV congestive heart failure. Bal-
oon valvuloplasty had been previously attempted in four
ases, but either failed or led to early valve restenosis.
ransthoracic and transesophageal echocardiography dem-
nstrated in all cases a heavily calcified aortic valve (bicuspid
n Patient 1 and tricuspid in all other cases), with a valve
rea0.6 cm2 by the continuity equation, and in all but one
atient (Patient 2), a low transvalvular gradient (50 mm
g) due to severe left ventricular dysfunction. Moderate to
evere aortic regurgitation was present in four patients and
itral regurgitation in five patients. Detailed echocardio-
raphic parameters are shown in Table 2. Only one patient
Patient 6) had associated coronary artery disease (right
oronary occlusion at the ostium).
Approval of our institutional ethic committee for com-
assionate PHV implantation was obtained for each case,
nd all patients and their closest relatives gave informed
onsent.
rocedure. Each procedure was performed under local
nesthesia and mild sedation. Aspirin (160 mg) and clopi-
Abbreviations and Acronyms
PHV  percutaneous heart valve
NYHA  New York Heart Associationogrel (300 mg) were administered the day before the lrocedure. In all cases, the anterograde trans-septal ap-
roach was used for PHV implantation, as previously
escribed (14). Briefly, basal hemodynamic parameters,
upra-aortic, left ventricular, and coronary angiograms were
rst obtained. Trans-septal catheterization was performed
rom the right femoral vein, and heparin 5,000 IU was
dministered intravenously. A 7-F flotation balloon catheter
as used for anterograde crossing of the aortic valve, and a
tiff 0.035-inch guide wire was advanced through this
atheter to the descending aorta and externalized through
he left femoral artery using a catheter snare. The trans-
eptal puncture site was then dilated with a 10-mm balloon
atheter, and a 23-mm balloon catheter advanced from the
ight femoral vein was used to predilate the native aortic
alve. Using a mechanical crimping device, the PHV was
ecurely crimped over a 23- or 22-mm (last four cases)
iameter, 30-mm length balloon catheter (Z-Med II,
uMed Inc., Hopkinton, New York). Through a 24-F
heath (Cook, Bjaeverskov, Denmark) placed into the right
emoral vein, the PHV was advanced over the wire, across
he interatrial septum, and within the stenotic native valve.
The following steps of valve implantation are shown in
igure 2. In the antero-posterior view, the valvular calcifi-
ation and a frozen view of a supra-angiogram were used as
arkers to position the PHV at the mid-portion of the
ative aortic valve. In the last four cases, accurate position-
ng was further facilitated by the use of a 7-F Sones catheter
dvanced from the left femoral artery over the same guide
ire and placed in contact with the distal end of the delivery
alloon catheter. The Sones catheter also prevented antero-
rade dislodgement of the delivery balloon during inflation.
sing a 10/90 contrast/saline solution, PHV delivery was
btained by maximal balloon inflation followed by rapid
eflation. To improve the precision of PHV implantation,
n Patients 3 and 5, rapid cardiac pacing (200 to 220
eats/min) of the right ventricle was undertaken during
HV delivery to decrease aortic blood flow and prevent the
isk of PHV migration during balloon inflation. The deliv-
ry balloon and the guide wire were withdrawn immediately
fter PHV delivery. Hemodynamic assessment and supra-
igure 1. Upper view of the percutaneous heart valve, made of three
eaflets of equine pericardium inserted within a stainless steel stent.
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Percutaneous Heart Valve in Aortic Stenosis February 18, 2004:698–703ortic, left ventricular, and selective coronary angiograms (in
he last four patients) were then performed as well as
ransthoracic and transesophageal echocardiography. The
enous puncture sites were closed by manual compression
hereas puncture closure devices (Angio-Seal, St. Jude
edical Europe, Zaventem, Belgium) were used to close
he arterial entry sites. All patients were closely monitored
uring follow-up, including clinical assessments and se-
uential transthoracic echocardiography and Doppler exam-
nations at day 1 and weekly thereafter. The continuity
quation was used to evaluate the PHV valve area during
ollow-up. Post-procedural treatment included aspirin (160
g) and clopidogrel (75 mg) daily. Subcutaneous low
olecular weight heparin (enoxaparin, 40 mg/day) was
dministered during the hospitalization stay. No oral anti-
oagulation was given.
tatistical analysis. Comparison of echocardiographic
ariables before, after PHV implantation, and on follow-up
as performed using the nonparametric Wilcoxon rank-
um test. Differences were considered significant at p 
.05. Values are expressed as mean  standard deviation.
ESULTS
mmediate results. The PHV was successfully and accu-
ately delivered in the subcoronary position in all but one
atient. This patient (Patient 2) was in cardiogenic shock,
nd had severe aortic stenosis associated with massive aortic
egurgitation due to a previous balloon aortic valvuloplasty-
nduced valve tear. The balloon-PHV assembly was ejected
n the ascending aorta at the time of full balloon inflation,
able 1. Clinical Characteristics of the Patients
atient Age Gender Cardiovascular Comorbidities
1 57 M Severe PAD, aorto-bifemoral bypass, recen
occlusion of the right limb, subacute leg
2 80 M Massive aortic regurgitation
3 91 M Pacemaker for syncopal complete AV block
4 63 M —
5 80 F Hypertension
6 77 M Inferior MI (RCA occlusion), previous stro
left hemispheric sequela; porcelain aorta
V  atrioventricular; COPD  chronic obstructive pulmonary disease; MI  myo
able 2. Echocardiographic Characteristics of the Patients
Patient
Mean Gradient (mm Hg)
Pre- Post- Follow-Up Pre-
1 35 5 8 0.60
3 56 4 6 0.50
4 30 2 4 0.40
5 38 6 6 0.43
6 31 11 13 0.52
ean  SD 38  11 5.6  3.4* 7.4  3.4* 0.49  0.08
ollow-up obtained at two weeks (Patient 3) and four weeks (Patients 1, 4, 5, and 6
AR  aortic regurgitation; AVA  aortic valve area; EF  left ventricular ejection frand the patient died shortly thereafter. On autopsy, the
alve leaflets were disconnected from the annulus on one-
hird of its circumference. In all other cases, the PHV
emained strongly anchored after delivery within the native
alve. No residual gradient was observed on simultaneous
ortic and ventricular pressure recordings. Post-implantation
upra-aortic angiography revealed mild (three cases) or
evere (two cases) aortic regurgitation and patent coronary
rteries. Coronary ostia were consistently above the upper
argin of the PHV on selective coronary angiography. The
HV function was dramatically improved on post-
rocedure echocardiographic evaluation (Table 2), with an
ncrease in aortic valve area from 0.49 0.08 cm2 to 1.66
.13 cm2 (p 0.04) and a decrease in transvalvular gradient
rom 38  11 mm Hg to 5.6  3.4 mm Hg (p  0.04).
ortic regurgitation was paravalvular in all cases. During the
rocedure, hemodynamic collapse occurred in Patients 2
nd 6 after balloon pre-dilation requiring transient external
ardiac massage and adrenalin infusion. However, PHV
mplantation (which, in Patient 6, was performed during
lectromechanical dissociation and external cardiac mas-
age) could be accomplished and was instantaneously fol-
owed by full hemodynamic recovery. No other complica-
ions ensued. Mean duration of the procedure was 134 23
in, and mean fluoroscopy time was 28  14 min.
linical course. The procedure was followed in all cases by
ramatic clinical improvement, with immediate and sus-
ained reduction of signs of heart failure. The initial three
atients who survived the procedure (Patients 1, 3, and 4)
ied of non-cardiac complication at 18, 4, and 2 weeks,
Noncardiac Comorbidities
mia
Lung cancer (left lobectomy), silicosis; chronic pancreatitis
Recent stroke (1 month); chronic renal failure; asbestosis;
prostate cancer
Cachexia (bedridden 1 month, eschars); very old age (90 yrs)
Evolving rectal adenocarcinoma; severe COPD; chronic renal
failure
Polymetastatic (lung and bones) breast cancer with chest
radiotherapy; COPD; kyphoscoliosis
th Chronic renal failure
l infarction; PAD  peripheral artery disease; RCA  right coronary artery.
A (cm2) AR (0–4) EF (%)
Post- Follow-Up Pre- Post- Pre- Follow-Up
1.82 1.64 0 1 10 22
1.70 1.65 2 3 29 40
1.74 1.70 0 1 28 42
1.52 1.62 1 1 34 53
1.62 1.55 2 3 19 48
 0.13* 1.63  0.05* 24  9.5 41  12*
0.04 compared to baseline.t
ische
ke wiAV
1.66
). *p 
ction; Pre- and Post-  pre- and post-implantation of percutaneous heart valve.
r
a
(
9
p
r
t
c
f
E
m
a
v
b
m
9
s
s
c
D
T
b
s
t
t
c
P
w
e
s
w
b
a
h
a
s
i
o
d
t
P
t
fl
a
c
e
m
c
F
g
o
r
( orona
701JACC Vol. 43, No. 4, 2004 Cribier et al.
February 18, 2004:698–703 Percutaneous Heart Valve in Aortic Stenosisespectively. Causes of death were complications of leg
mputation due to long-standing peripheral vascular disease
Patient 1); an acute abdominal syndrome (Patient 3; this
1-year-old individual had been discharged at day 10
ost-procedure with no signs of heart failure); and hemor-
hage from rectal carcinoma (Patient 4). The most recent
wo patients were discharged at days 12 and 15, and they are
linically stable at 8 weeks with no symptoms of heart
ailure.
chocardiographic assessment. The PHV function re-
ained normal and unchanged during follow-up with thin
nd mobile leaflets, no change in transvalvular gradient and
alve area, and stable paravalvular aortic regurgitation (Ta-
le 2). From baseline to last echocardiographic evaluation,
ean left ventricular ejection fraction increased from 24 
.5% to 41  12% (p  0.04). The cylindrical PHV frame
hape was maintained over time. Only mild transatrial
hunting was observed on color flow Doppler studies in all
ases.
ISCUSSION
his early experience confirms that a bioprosthetic valve can
e implanted percutaneously within the native diseased
tenotic aortic valve of patients with end-stage life-
hreatening calcific aortic stenosis, using standard interven-
igure 2. Sequential steps of implantation. (A) The percutaneous valve in
uide wire; PM  pacemaker lead in the right ventricle for brief period of
ver the guide wire from the left femoral artery. (B) Balloon inflation for va
egurgitation. (D) Right anterior oblique-cranial view of the valve showin
E) and right (F) coronary angiogram post-implantation showing patent cional techniques under local anesthesia. This clinical appli- aation followed an animal model testing (11) in which the
HV could be delivered at various cardiac sites in the sheep
ith satisfactory immediate and short-term results. How-
ver, implantation within the native aortic valve in the
ubcoronary position was technically difficult in this model,
hich varies considerably from humans, with limited space
etween the coronary ostia and the mitral valve (6 mm),
nd a lack of calcific or fibrotic valvular lesion explaining the
igh rate of early (15 days) PHV migration.
Implantation of PHV leads to dramatic hemodynamic
nd clinical improvement with early and mid-term relief of
igns of heart failure. The PHV can be accurately delivered
n the subcoronary position without impairing the coronary
stia or the mitral valve, and attaches firmly within the
iseased native valve. However, pre-procedure valve disrup-
ion can impair the anchorage of the PHV, as shown in
atient 2. To avoid impinging of the coronary ostia at the
ime of PHV delivery, calcification of the native valve on
uoroscopy and the frozen selected frame of the supra-
ortic angiogram showing the onset of the left main
oronary artery were used as markers. This clinical experi-
nce confirmed our postmortem observations that a 14-
m-long stent positioned at the mid-aortic valve does not
over the coronary ostia.
The anterograde trans-septal approach that was used in
on across the native calcific aortic valve before delivery. GW  extra-stiff
pacing at the time of balloon inflation; Sones  Sones catheter advanced
livery. (C) Post-implantation supra-aortic angiogram showing mild aortic
circular stent frame pushing away the calcified native valve. Selective left
ry ostia.positi
rapid
lve de
g thell cases has several advantages over the more commonly
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Percutaneous Heart Valve in Aortic Stenosis February 18, 2004:698–703sed retrograde approach to reach the aortic valve. This
oute allows percutaneous insertion of the PHV through a
4-F sheath in the femoral vein under local anesthesia,
liminates the risk of arterial thrombosis, dissection, or
upture, and offers more predictable valve delivery since the
HV crosses the less diseased myocardial surface of the
ortic leaflets and is coincident with the direction of blood
ow. However, special attention must be given at each step
f the procedure to maintain a large guide wire loop inside
he left ventricle so as to avoid traction on the anterior
itral valve leaflet with subsequent severe mitral regurgita-
ion and hemodynamic collapse. This complication occurred
n two patients of this series when the wire was incidentally
traightened from the mitral valve to the aortic valve.
A brief period of rapid (200 to 220 beats/min) cardiac
acing causes sufficient impairment of cardiac output during
HV delivery to facilitate precise positioning of the device.
his technique, previously used in our center in several
alloon aortic valvuloplasty procedures, leads to optimal
tabilization of the inflated balloon across the aortic valve.
he 10-mm balloon used to dilate the interatrial septum did
ot create significant residual shunting as confirmed by
chocardiography and Doppler imaging. However, in pa-
ients with undiseased femoral arteries of suitable size for
nsertion of a 24-F sheath, the more familiar retrograde
ortic approach might be faster and easier to manage for
ome interventional operators. Furthermore, it would avoid
he potential risks of trans-septal catheterization and mitral
alve crossing-induced mitral regurgitation and subsequent
emodynamic collapse.
An aortic orifice valve area averaging 1.7 cm2 with
inimal trans-PHV gradient was instantaneously obtained
n all successful cases after PHV implantation. This repre-
ents a 3-fold improvement compared with baseline valve
reas and was consistently associated with a striking early
mprovement of left ventricular function and subsequent
linical benefit. The results after PHV implantation are
ignificantly better than those obtained after balloon aortic
alvuloplasty, which rarely provides an increase in valve area
bove 0.8 cm2 (3,4). Of note, even in Patient 1, who had no
igure 3. Postmortem findings in Patient 3 (upper views). (Left to right)
ree space between the percutaneous valve and the native valve confirmingyocardial contractility reserve, and in whom left ventric- mlar ejection fraction remained severely impaired (20%),
HV implantation was followed by marked relief of signs of
eart failure. Although ex-vivo studies indicate several-year
alve durability, the stability of PHV function over time
equires careful assessment and meticulous long-term pa-
ient follow-up. However, in this selected population of
ying patients in whom severe aortic stenosis is associated
ith multiple potentially fatal comorbidities, prolonged
urvival is unlikely, as shown by the post-procedure early
eaths from non-cardiac cause in three of the patients.
Paravalvular aortic regurgitation was noted in all patients
ost-PHV implantation. Echocardiography indicated that
here might be imperfect apposition of the PHV stent frame
gainst the diseased native valvular structures at the site of
alcific nodules. This was confirmed on postmortem obser-
ation in Patient 3 (Fig. 3). Although paravalvular aortic
egurgitation did not blunt the early improvement in left
entricular function and clinical status after relief of the
ortic valve blockage, severe paravalvular aortic regurgitation
ight impair long-term clinical outcomes after PHV im-
lantation. Larger maximal stent diameters and other im-
rovements in stent design might decrease the incidence
nd severity of paravalvular aortic regurgitation in the
uture.
Because the PHV is a bioprosthetic valve inserted within
stainless steel stent, the anticoagulant regimen was limited
o antiplatelet therapy (aspirin and clopidogrel), without
ong-term oral direct thrombin inhibitors. Prophylactic
nticoagulation with intravenous heparin in the first two
ases, or low molecular weight heparin in the next cases, was
dded only during the hospital convalescent period.
An ongoing pilot clinical trial in our center (I-REVIVE
tudy) will allow further refinement of the technique and
ssessment of both short- and long-term clinical outcomes.
nce the operator technique achieves consistent predictable
esults and beneficial long-term clinical outcomes can be
emonstrated, pivotal multicenter clinical trials will be
equired to determine the role of this promising new
herapeutic approach for patients with end-stage calcific
ortic stenosis that is not amenable by surgical valve replace-
coronary (RCA) ostium (arrow); left coronary (LM) ostium (arrow); and
mechanism of the paravalvular leak (PL).Right
theent.
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